{
  "docId": "019de072-468c-700c-89db-ca818deece7f",
  "docSlug": "40fd19b5105eee76fe8edee20250e12b",
  "documentTitle": "AN2 Therapeutics | IPO Presentation Deck | 27 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 13,
  "pageCount": 27,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_disclosure",
  "function": "cite_precedent",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Includes boxed warning information for a competitor/reference drug.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-468c-700c-89db-ca818deece7f/13",
  "deckHref": "/decks/019de072-468c-700c-89db-ca818deece7f",
  "deckJsonHref": "/decks/019de072-468c-700c-89db-ca818deece7f.json",
  "deckAnchorHref": "/decks/019de072-468c-700c-89db-ca818deece7f#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.68,
        "x": 0.29,
        "y": 0.54
      },
      "kind": "callout",
      "text": "Arikayce Boxed Warnings: Associated with an increased risk of respiratory conditions (hypersensitivity pneumonitis, bronchospasm, exacerbation of underlying lung disease and hemoptysis) that have led to hospitalizations in some cases. Other common side effects: dysphonia, cough, ototoxicity, upper airway irritation, musculoskeletal pain, fatigue, diarrhea and nausea",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec99d4c2-556d-4136-8296-c4b16348fa15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "paragraph",
      "text": "Arikayce (Inhaled liposomal amikacin): first and only FDA-approved NTM lung disease drug. Arikayce is associated with a high discontinuation rate and increased adverse events versus SoC therapy alone",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83933bb7-0d59-44a3-abb2-53514ed3abf8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.68,
        "x": 0.29,
        "y": 0.14
      },
      "kind": "table",
      "text": "CONVERT Study Parameter | Arikayce | Control | Culture-converted by month 6 | 29% | 9% | Withdrawn from study | 20% | 9% | Upper respiratory adverse events | 18% | 2% | Ototoxicity | 17% | 10%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cea4d657-9e68-46bf-b1b3-1846176a71d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.29,
        "y": 0.06
      },
      "kind": "title",
      "text": "Arikayce Pivotal Study (CONVERT) Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fda8f084-42d2-4672-920c-559dad375271",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 27,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "5c43fe0e-f0f3-4ff4-8709-c2c99c61b351",
      "evidence": "The deck starts and ends with the company's mission",
      "position": 1,
      "objective": "Present a clear mission and vision for AN2 Therapeutics",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}